|[June 23, 2014]
Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
MUNICH --(Business Wire)--
AG, which offers a unique approach to tissue
diagnostics aimed at helping physicians improve treatment, said that
it has closed a round of financing for € 15 million. The round was led
by Wellington Partners, a leading pan-European venture capital firm.
Gilde Healthcare co-led the financing round and was joined by other
existing investors Cipio Partners and TVM Capital in the financing. In
conjunction with the financing, Dr. Rainer Strohmenger, General Partner
and Managing Director for Wellington, will join Definiens' Board of
The new funds will allow Definiens to grow its global business in digital
pathology image analysis and expand into digital tissue diagnostics.
Major investments will be made in executing the company's Tissue
Phenomics strategy, enabling partnerships with leading medical centers
and pharmaceutical companies to advance the diagnosis and treatment of
cancer. Tissue Phenomics is based on Definiens' proprietary Cognition
Network Technology®, invented by Nobel (News - Alert) laureate and founder Prof. Gerd
Binnig and involves a unique big data approach to develop new
tissue-based diagnostic tests for oncology and immunotherapy. Using
these new diagnostic tests will allow for better prediction of patient
outcomes and identiication of drug responders, thereby bridging the gap
between genomic data and cancer outcomes.
Dr. Rainer Strohmenger, General Partner and Managing Director at
Wellington Partners, commented, "We have been following Definiens for
many years and have always been impressed by the visionary concept and
exciting technology the company has. We believe that Definiens now is
approaching an inflection point which will have a significant impact on
the growth potential and strategic value of this business for the
leading players in imaging, diagnostics and oncology drug development."
Thomas Heydler, CEO at Definiens, stated, "Wellington Partners is one of
the few investors experienced in both diagnostics and healthcare IT with
a strong track record of successfully building and capturing value from
businesses in these areas. We are honored to add Wellington to our
investor base and welcome Dr. Strohmenger to our Board of Directors.
This financing will allow us to pursue our aggressive growth strategy to
further expand our global leadership in Tissue Phenomics."
Dr. Gerald Möller, Chairman at Definiens AG, added, "The use of
state-of-the-art information technology in medicine will dramatically
improve the way patients will be diagnosed and treated and the way new
drugs and diagnostic tests will be developed. This change will not only
lead to improved patient outcomes but also drive personalized medicine
forward, and I am convinced that Definiens will play an important role
in accelerating this change, especially in the fields of pathology,
cancer, and immunotherapy. The fact that we have attracted this
significant financing with new lead investor Wellington is another
confirmation of Definiens' strong position."
About Wellington Partners
Wellington Partners is among the most successful pan-European Venture
Capital firms. With more than € 850 million under management and offices
in Munich, London and Zurich, Wellington Partners invests in start-up
companies throughout Europe that have the potential to become global
leaders in the areas of digital media, resource efficiency and life
Since 1998, Wellington Partners has invested in more than 100 companies,
including publicly listed firms like Actelion, Evolva, Genticel,
Implanet, Noemalife, Oxford Immunotec, Supersonic Imagine, Wavelight
(acquired by Alcon) and Xing as well as privately held companies like
AyoxxA, Grandis (acquired by Novartis), immatics, invendo medical, MPM
Medical, MTM Laboratories (acquired by Roche), Oxagen, Quanta, Sapiens,
Sensimed, Symetis and Spotify (News - Alert). For further information, please visit www.wellington-partners.com.
Definiens is the global leader in Tissue Phenomics™ for discovery and
diagnostics development in oncology and provides image analysis
solutions for life sciences. Definiens' technology provides detailed
tissue biomarker readouts from slide images and enables the correlation
of this information with other key clinical or genomic information, an
approach known as Tissue Phenomics™. Definiens helps pharmaceutical and
biotechnology companies, research institutions, clinical service
organizations and pathologists to generate new knowledge and support
better decisions in research, diagnostics and therapy.
Definiens' vision is to open new fields of research, to contribute to
development of personalized medicine, and to significantly improve the
quality of patients' lives. Definiens is headquartered in Munich,
Germany and has its North American headquarters in Carlsbad, CA (News - Alert). Further
information is available at www.definiens.com.
[ Back To TMCnet.com's Homepage ]